AR088845A1 - Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel - Google Patents

Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel

Info

Publication number
AR088845A1
AR088845A1 ARP120104260A ARP120104260A AR088845A1 AR 088845 A1 AR088845 A1 AR 088845A1 AR P120104260 A ARP120104260 A AR P120104260A AR P120104260 A ARP120104260 A AR P120104260A AR 088845 A1 AR088845 A1 AR 088845A1
Authority
AR
Argentina
Prior art keywords
tetrahydro
quinoline
treatment
skin diseases
ilmetil
Prior art date
Application number
ARP120104260A
Other languages
English (en)
Spanish (es)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR088845(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR088845A1 publication Critical patent/AR088845A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
ARP120104260A 2011-11-10 2012-11-12 Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel AR088845A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161558104P 2011-11-10 2011-11-10

Publications (1)

Publication Number Publication Date
AR088845A1 true AR088845A1 (es) 2014-07-10

Family

ID=47178364

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104260A AR088845A1 (es) 2011-11-10 2012-11-12 Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel

Country Status (22)

Country Link
US (4) US20130123303A1 (cg-RX-API-DMAC7.html)
EP (3) EP3763370A1 (cg-RX-API-DMAC7.html)
JP (2) JP6359456B2 (cg-RX-API-DMAC7.html)
KR (1) KR102004563B1 (cg-RX-API-DMAC7.html)
CN (1) CN104136029A (cg-RX-API-DMAC7.html)
AR (1) AR088845A1 (cg-RX-API-DMAC7.html)
AU (2) AU2012335803B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014011336A2 (cg-RX-API-DMAC7.html)
CA (1) CA2855005C (cg-RX-API-DMAC7.html)
CL (1) CL2014001242A1 (cg-RX-API-DMAC7.html)
DK (1) DK2776034T3 (cg-RX-API-DMAC7.html)
ES (1) ES2635421T3 (cg-RX-API-DMAC7.html)
IL (3) IL232483B (cg-RX-API-DMAC7.html)
MX (1) MX350662B (cg-RX-API-DMAC7.html)
MY (1) MY182553A (cg-RX-API-DMAC7.html)
PH (1) PH12014501051A1 (cg-RX-API-DMAC7.html)
RU (2) RU2667645C1 (cg-RX-API-DMAC7.html)
SG (3) SG10201609145PA (cg-RX-API-DMAC7.html)
TW (3) TW202014189A (cg-RX-API-DMAC7.html)
UA (1) UA109359C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013070861A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201403396B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
RU2015148910A (ru) * 2013-05-06 2017-06-13 Аллерган, Инк. Альфа-адренергические агонисты для лечения повреждения тканей
FR3061434B1 (fr) * 2017-01-04 2019-07-12 Pierre Fabre Dermo-Cosmetique Composition cosmetique comprenant une association d'huile de pongamia et de pentylene glycol 4-t-butylcyclohexanol pour lutter contre la rosacee
RU2727695C1 (ru) * 2020-02-13 2020-07-22 Мурад Умарович Магомедов Способ комплексного лечения ринофимы

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1075265B1 (en) * 1998-05-08 2006-03-08 The University Of Miami Use of tetracyclines for treating meibomian gland disease
WO2004073708A1 (en) * 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
US20010049369A1 (en) * 2000-02-10 2001-12-06 Jablonski Monica M. Brimonidine compositions and methods for retinal degeneration
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US20040146539A1 (en) * 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
AU2004293105B2 (en) * 2003-11-20 2010-09-09 Othera Holding, Inc. Amelioration of macular degeneration and other ophthalmic diseases
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
DK1761266T3 (da) * 2004-05-25 2013-08-05 Galderma Pharma Sa Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
US20070203144A1 (en) * 2006-01-17 2007-08-30 Allergan, Inc. Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
US7323477B2 (en) * 2006-02-02 2008-01-29 Allergan, Inc. 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
RU2321399C1 (ru) * 2006-06-01 2008-04-10 Федеральное государственное учреждение "Нижегородский научно-исследовательский кожно-венерологический институт Федерального агентства по здравоохранению и социальному развитию" Способ лечения больных розацеа
US20090005450A1 (en) * 2007-04-09 2009-01-01 Belinda Tsao Nivaggioli Use of creatine compounds for the treatment of eye disorders
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
US8455548B2 (en) * 2007-10-18 2013-06-04 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
US8293742B2 (en) * 2008-08-01 2012-10-23 Alpha Synergy Development, Inc. Preferential vasoconstriction compositions and methods of use
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
FR2942138A1 (fr) * 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
US20110224216A1 (en) * 2009-10-26 2011-09-15 Galderma Laboratories Inc. Methods of Treating or Preventing Acute Erythema
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
AU2011231543B2 (en) * 2010-03-26 2015-01-15 Galderma Research & Development Improved methods and compositions for safe and effective treatment of erythema
CA2792649A1 (en) * 2010-03-26 2011-09-29 Michael Graeber Improved methods and compositions for safe and effective treatment of telangiectasia
EP2600832A1 (en) * 2010-08-06 2013-06-12 Galderma Research & Development Combination of compounds for treating or preventing skin diseases

Also Published As

Publication number Publication date
EP2776034B1 (en) 2017-03-22
WO2013070861A1 (en) 2013-05-16
SG11201402246RA (en) 2014-06-27
IL232483A0 (en) 2014-06-30
KR20140107237A (ko) 2014-09-04
JP6526737B2 (ja) 2019-06-05
IL261269A (en) 2018-10-31
AU2016216627B2 (en) 2017-10-19
IL232483B (en) 2018-10-31
UA109359C2 (xx) 2015-08-10
DK2776034T3 (en) 2017-07-10
AU2012335803B2 (en) 2016-05-26
CN104136029A (zh) 2014-11-05
EP3763370A1 (en) 2021-01-13
RU2667645C1 (ru) 2018-09-21
RU2630978C2 (ru) 2017-09-15
US20170095466A1 (en) 2017-04-06
RU2014122758A (ru) 2015-12-20
JP2017149767A (ja) 2017-08-31
SG10201809506TA (en) 2018-11-29
NZ624771A (en) 2016-11-25
SG10201609145PA (en) 2016-12-29
TW201713338A (zh) 2017-04-16
TWI708604B (zh) 2020-11-01
TWI580424B (zh) 2017-05-01
MY182553A (en) 2021-01-25
US20150231128A1 (en) 2015-08-20
US20130123303A1 (en) 2013-05-16
ES2635421T3 (es) 2017-10-03
ZA201403396B (en) 2015-07-29
AU2012335803A1 (en) 2014-05-29
EP3184110B1 (en) 2020-10-07
US9308201B2 (en) 2016-04-12
CA2855005C (en) 2016-11-22
US20160051534A1 (en) 2016-02-25
KR102004563B1 (ko) 2019-07-26
EP2776034A1 (en) 2014-09-17
PH12014501051A1 (en) 2022-11-02
MX350662B (es) 2017-09-13
BR112014011336A2 (pt) 2017-05-02
JP6359456B2 (ja) 2018-07-18
IL268757A (en) 2019-10-31
EP3184110A1 (en) 2017-06-28
CA2855005A1 (en) 2013-05-16
TW201328694A (zh) 2013-07-16
AU2016216627A1 (en) 2016-09-08
MX2014005640A (es) 2014-09-22
JP2014533271A (ja) 2014-12-11
CL2014001242A1 (es) 2014-11-14
TW202014189A (zh) 2020-04-16

Similar Documents

Publication Publication Date Title
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY34974A (es) Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
DOP2014000008A (es) 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
ECSP12011834A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, métodos para su tratamiento y sus usos.
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
MX343215B (es) Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos.
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
AR090241A1 (es) INHIBIDORES DE LA b-SECRETASA
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
MX350666B (es) Composiciones y sus usos para tratar hiperuricemia y trastornos metabolicos asociados con hiperuricemia.
ECSP14013275A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
MX2019004484A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
UY36124A (es) Derivados de carboxamida
DOP2013000314A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
UY37745A (es) Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias
MX381932B (es) Composicion intranasal que comprende betahistina.
AR100153A1 (es) Medicamento

Legal Events

Date Code Title Description
FB Suspension of granting procedure